News

Moderna (MRNA) skyrocketed to fame during the pandemic, delivering one of the first mRNA-based Covid-19 vaccines and quickly ...
Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...
The CDC expanded RSV vaccine recommendations to include adults aged 50 and above who have underlying health conditions ...
Moderna, Inc.'s Q2 2025 earnings highlight a steep revenue decline post-pandemic, with just $0.1bn in revenue and a $(0.8bn) ...
The company reported a net loss of $825 million for the quarter. Additionally, Moderna announced a $300 million reduction at the high end of their 2025 projected revenue range due to a timing shift of ...